MALLINCKRODT INC /MO
10-K, EX-27, 2000-08-28
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: MALLINCKRODT INC /MO, 10-K, EX-23.1, 2000-08-28
Next: NVEST FUNDS TRUST II, NT-NSAR, 2000-08-28



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED STATEMENTS OF OPERATIONS OF THE
COMPANY'S FORM 10-K, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                              26
<SECURITIES>                                         0
<RECEIVABLES>                                      506
<ALLOWANCES>                                        18
<INVENTORY>                                        447
<CURRENT-ASSETS>                                 1,134
<PP&E>                                           1,531
<DEPRECIATION>                                     678
<TOTAL-ASSETS>                                   3,469
<CURRENT-LIABILITIES>                            1,064
<BONDS>                                            541
                                0
                                         11
<COMMON>                                            87
<OTHER-SE>                                       1,043
<TOTAL-LIABILITY-AND-EQUITY>                     3,469
<SALES>                                          2,653
<TOTAL-REVENUES>                                 2,653
<CGS>                                            1,475
<TOTAL-COSTS>                                    2,325
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  75
<INCOME-PRETAX>                                    295
<INCOME-TAX>                                        90
<INCOME-CONTINUING>                                205
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       205
<EPS-BASIC>                                       2.97
<EPS-DILUTED>                                     2.96


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission